There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.

The present invention relates to an oral thin film comprising at least one polymer and at least one pharmaceutically active agent, wherein the concentration of the at least one pharmaceutically active agent in the oral thin film is greater than the saturation concentration of the at least one pharmaceutically active agent in the oral thin film, and wherein the oral thin film comprises at least one material which serves as crystal nucleus for the at least one pharmaceutically active agent, to a method for producing said oral thin film, and to the use of said oral thin film as a medicament.

A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

The present invention provides compositions of GHK-Cu/copper tripeptide to avoid first pass metabolism including transdermal patch compositions. The GHK-Cu/copper tripeptide is preferably in the form of a gel reservoir having polymer and one or more penetration enhancers. The transdermal compositions release GHK-Cu/copper tripeptide in various release patterns to allow 1-7 times delivery of GHK-Cu/copper tripeptide in a week. The transdermal compositions instantly achieve steady state in rats and the concentration is sustained over at least 12 hrs, preferably over 24 hrs.

The invention relates to a sprayable liquid solution for the local delivery of lidocaine to the epidermis (skin), gingiva, oral mucosa or mucosal lining of the pharynx, and to a method of providing local anesthesia by administering this composition. The solution comprises at least 40% w/w lidocaine, or about 2% to about 50% w/w/ lidocaine.

The present invention relates to a transdermal absorption preparation that can maintain a blood concentration sufficient to exert the efficacy of tandospirone, and also shows good storage stability against heat, humidity, and light. According to the present invention, a transdermal absorption preparation containing tandospirone or a pharmaceutically acceptable salt thereof, and levulinic acid, which is superior in the skin permeability of tandospirone or a pharmaceutically acceptable salt thereof in the preparation, and shows good preservation stability against heat and light can be provided.

Self-supporting film unit dosage forms for oral transmucosal delivery are disclosed herein containing an active. These film dosage forms for oral transmucosal delivery have a substantially equivalent pharmacokinetic profile to dosage forms administered by another route or in another dosage form (e.g., tablet, patch) and yet have a different amount of active contained therein.

The present invention relates to methods and compositions for the delivery of cosmetics and medicants. In some embodiments, the invention relates to compositions comprising both hydrophobic and hydrophilic polymers. In preferred embodiments, the invention relates to the delivery of peptides, small molecules and other bioactive compounds using the compositions and methods disclosed herein.

The present invention relates to methods and compositions for the delivery of cosmetics and medicants. In some embodiments, the invention relates to compositions comprising both hydrophobic and hydrophilic polymers. In preferred embodiments, the invention relates to the delivery of peptides, small molecules and other bioactive compounds using the compositions and methods disclosed herein.

Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte-activating moiety.